NCT04752631 (ROSE-TNK) is a Phase 4 clinical trial of Tenecteplase in Stroke, sponsored by General Hospital of Shenyang Military Region.

Who is sponsoring NCT04752631?

NCT04752631 is sponsored by General Hospital of Shenyang Military Region.

What drugs are being tested in NCT04752631?

Interventions in NCT04752631: Tenecteplase.

Is NCT04752631 still recruiting?

NCT04752631 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT04752631: ROSE-TNK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK

Completed Phase 4 Last updated 2 August 2022

What this trial tests

Phase 4 trial testing Tenecteplase in Stroke in 80 participants. Completed in 24 July 2022.

Timeline

9 March 2021

Primary endpoint
24 July 2022

24 July 2022

Quick facts

Lead sponsor	General Hospital of Shenyang Military Region
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	9 March 2021
Primary completion	24 July 2022
Estimated completion	24 July 2022
Sites	1 location across China

Drugs / interventions tested

Tenecteplase (TENECTEPLASE) — full drug profile →

Conditions studied

Stroke — all drugs for Stroke →

Sponsor

General Hospital of Shenyang Military Region

Who can join

Adults 18 to 80, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Wang L, Hao M, Wu N, Wu S, et al · · 2024 · cited 48× · PMID 38686848 · DOI 10.1161/jaha.123.031692
Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5-24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study.
Wang L, Dai YJ, Cui Y, Zhang H, et al · · 2023 · cited 22× · PMID 37608533 · DOI 10.5853/jos.2023.00668
Tenecteplase in Ischemic Stroke: Challenge and Opportunity.
Li G, Wang C, Wang S, Xiong Y, et al · · 2022 · cited 12× · PMID 35586365 · DOI 10.2147/ndt.s360967
Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns.
Dong Y, Sui Y, Cheng X, Wang DZ. · · 2022 · cited 7× · PMID 34667106 · DOI 10.1136/svn-2021-001321

Verify or expand the search:

Other trials of Tenecteplase

Trials testing the same drug.

NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT06621121 — A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Strok · recruiting

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other General Hospital of Shenyang Military Region trials

Trials by the same sponsor.

NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07462546 — Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04752631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by General Hospital of Shenyang Military Region
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04752631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing